Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 19, 2026

Evotec, BMS Gain Second FDA IND Acceptance for Molecular Glue Degrader

Listen
0:00 / 0:00

Key Takeaways

  • A second IND acceptance suggests iterative generation of CELMoD molecular glue candidates, extending beyond BMS-986506, which began phase 1 in advanced clear cell renal cell carcinoma in March 2026.
  • Platform synergy combines industrial-scale proteomics/transcriptomics and AI-supported analytics with a pharma CELMoD library to identify substrates, nominate leads, and progress into lead optimization.
SHOW MORE

A second cereblon E3 ligase modulator from the Evotec and Bristol Myers Squibb degrader partnership is set to begin phase 1 testing in 2027.

Evotec announced on November 19, 2026, that its protein degradation partnership with Bristol Myers Squibb has received a second investigational new drug (IND) application acceptance from FDA, expanding the partnered molecular glue pipeline.¹ The second candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter a phase 1 clinical trial in 2027.¹

Key facts

  • Partners: Evotec and Bristol Myers Squibb (collaboration begun 2018 with Celgene)
  • Modality: Molecular glue degraders; cereblon E3 ligase modulators (CELMoDs)
  • Milestone: Second investigational new drug application accepted by the FDA
  • Second candidate: CELMoD; name, target, and indication not disclosed
  • Expected start: Phase 1 trial in 2027
  • First candidate: BMS-986506, in phase 1 in advanced clear cell renal cell carcinoma
  • First candidate milestone: $10 million paid to Evotec on study initiation, March 2026
  • Evotec platforms: PanOmics screening and PanHunter data analysis
  • Partner contribution: Bristol Myers Squibb's CELMoD agent library
  • Deal terms: Financial terms of the second acceptance not disclosed

“The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform,” said Joanna Holbrook, PhD, chief scientific officer of Evotec, in a company press release.¹

What has the partnership produced so far?

The first candidate from the collaboration, BMS-986506, entered a phase 1 trial in advanced clear cell renal cell carcinoma in March 2026, triggering a $10 million milestone payment to Evotec.¹,² Bristol Myers Squibb initiated that first-in-human study.² Dr Holbrook said the second acceptance reinforces the value of the collaboration and strengthens confidence in the platform's potential to generate a growing pipeline of investigational candidates.¹

How are the companies working together?

The partnership began in 2018 with Celgene, now Bristol Myers Squibb, and was expanded in 2022.¹ It pairs Evotec's multi-omics screening, artificial intelligence (AI)-supported data analytics, and drug design capabilities with Bristol Myers Squibb's CELMoD agent library.¹ Evotec applies proteomics and transcriptomics at industrial scale through its PanOmics platform and analyzes the resulting data sets with PanHunter, which supports identification and advancement of CELMoDs into lead optimization, according to the company.¹

What are molecular glue degraders, and how do they work?

Molecular glue degraders induce interactions between an E3 ubiquitin ligase and a target protein, leading to ubiquitination and degradation of the recruited protein.¹ By inducing neomorphic interactions between cereblon and substrate proteins, CELMoDs enable pharmacological modulation of proteins that may not be amenable to traditional inhibitor or agonist approaches.¹

Conventional small molecules act by interfering with protein activity, a limitation to agonistic or antagonistic function that Evotec said renders about 90% of proteins undruggable.¹ A 2025 review in Biochemical Pharmacology describes targeted protein degradation as an approach that harnesses the ubiquitin-proteasome system to selectively eliminate specific proteins and thereby fully abolish their activities, in contrast with traditional inhibitors that transiently suppress protein activity.³ The review characterizes molecular glues as low molecular weight compounds that act as a molecular bridge between a target protein and an E3 ligase, enabling degradation without requiring classical binding pockets.³

How does this fit broader degrader dealmaking?

Molecular glue degraders have drawn sustained pharmaceutical investment. In September 2025, Monte Rosa Therapeutics and Novartis announced a second collaboration, this one covering difficult-to-drug immunology targets, with a $120 million upfront payment and total potential value of up to $5.7 billion including option fees, milestones, and tiered royalties.⁴ That agreement extended a 2024 license covering Monte Rosa's VAV1-directed degraders.⁴ As in the Evotec collaboration, the discovery partner applies an AI-supported platform while the larger company takes later-stage development and commercialization.⁴

What are the limitations?

The Evotec announcement does not name the second candidate, its molecular target, or the indication it will be studied in, and it gives no trial start date beyond 2027. No clinical data have been reported for either candidate, and an IND acceptance permits clinical testing to begin rather than indicating efficacy or safety. Financial terms tied to the second acceptance were not disclosed. Evotec's characterization of its platform's repeatability and productivity is the company's own assessment, and the 90% undruggable figure is attributed to Evotec without a cited source.

References

  1. Evotec. Evotec and Bristol Myers Squibb advance strategic protein degradation partnership with second IND acceptance. Press release. Published November 19, 2026. Accessed November 19, 2026. https://www.evotec.com/news/evotec-and-bristol-myers-squibb-advance-strategic-protein-degradation-partnership-with-second-ind-acceptance
  2. Evotec. Evotec receives $10 million milestone from Bristol Myers Squibb protein degradation collaboration for clinical study initiation. Press release. Published March 19, 2026. Accessed November 19, 2026. https://www.evotec.com/news/evotec-receives-10-m-milestone-from-bristol-myers-squibb-protein-degradation-collaboration-for-clinical-study-initiation
  3. Eladl O. Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential. Biochem Pharmacol. 2025;242(Pt 3):117297. doi:10.1016/j.bcp.2025.117297
  4. Monte Rosa Therapeutics. Monte Rosa Therapeutics announces collaboration with Novartis for degraders to treat immune-mediated diseases. Press release. Published September 15, 2025. Accessed November 19, 2026. https://ir.monterosatx.com/news-releases/news-release-details/monte-rosa-therapeutics-announces-collaboration-novartis

Related to this article